Symbiomix Therapeutics, LLC

In a quiet week for approvals, the US Food and Drug Administration acted in two relatively underserved areas: the common condition bacterial vaginosis, where the FDA cleared Daré Biosciences’ Xaciato,

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Picks Up Perception’s R-Ketamine

Going by recent events, Lupin can count on new product launches in major markets like the US and EU to aid its FY2021 performance even while the outlook on production remains mixed, with benefits of

Going by recent events, Lupin Ltd. can count on new product launches in major markets like the US and EU to aid its FY2021 performance even while the outlook on production remains mixed with benefit